美敦力 In.Pact Admiral 药物涂层球囊获得CE认证用于晚期肾脏...

leonguo

Medtronic wins CE Mark for In.Pact Admiral DCB for end-stage renal disease

Medtronic (NYSE:MDT) said today its In.Pact admiral drug eluting balloon won CE Mark approval in the European Union for arteriovenous access to help maintain hemodialysis access in patients with end-stage renal disease.

The device is now cleared for preventing restenosis in hemodialysis access sites by opening up the artery and delivering paclitaxel to the vessel wall. A 40 cm catheter shaft will also be made available alongside the expanded indication for the device.

“For patients with hemodialysis, maintaining AV access is their lifeline to receiving the care they need to filter waste from their system. In the past, when the access site became stenosed, the only option was the use of a standard percutaneous transluminal angioplasty, which can result in the need for repeat procedures. The In.Pact Admiral DEB, in my experience, provides a safe and more effective way of managing AV access by preventing vascular restenosis, improving patency of dialysis fistulas and grafts, and reducing the need of repeat PTA procedures,” Dr. Konstantinos Katsanos of London’s St. Thomas’ Hospital said in a press release.

The In.Pact Admiral DCB received its initial CE Mark approval in the European Union in 2009 for treating peripheral artery disease, and won FDA approval in 2014 with indications for treating superficial femoral and popliteal arteries.

“In.Pact Admiral DEB, a best-in-class therapy for the treatment of superficial femoral artery disease, is now indicated in Europe for the treatment of AV access, providing a durable primary intervention that aids in extending time to re-intervention while preserving future treatment options. Improving lives and alleviating pain is a core piece of Medtronic’s mission, and through In.Pact Admiral DEB, we can help physicians treat patients with end-stage renal disease,” peripheral biz veep Brian Verrier said in a press release.

Last November, Fridley, Minn.-based Medtronic touted data from a pair of studies of its In.Pact Admiral drug-coated balloon, presented at the annual Vascular Interventional Advances conference in Las Vegas.

Researchers revealed the formal cost-effectiveness analysis of the U.S. cohort of Medtronic’s In.Pact SFA trial, and in-stent restenosis cohort data from its In.Pact Global study.

原文链接：http://www.massdevice.com/medtro ... tage-renal-disease/

江西魏工

学习学习一下

devstd

感谢分享感谢分享感谢分享

medphysics

medtech

谢谢分享

RTphysics

好文章，值得学习，顶起来

medstd

一刀杨幂上床，二刀上海买房。三刀台湾归降，四刀美帝叫娘。五刀星河翱翔，六刀宇宙称王。七刀女人长屌，八刀汉子变娘。九刀完爆山东蓝翔——切糕！